|1.||Kang, Kyung Koo: 10 articles (01/2007 - 06/2003)|
|2.||Yoo, Moohi: 7 articles (07/2010 - 03/2005)|
|3.||Kang, K K: 6 articles (10/2014 - 10/2000)|
|4.||Ahn, Gook Jun: 6 articles (10/2005 - 06/2003)|
|5.||Kim, Won Bae: 6 articles (01/2005 - 06/2003)|
|6.||Kim, Sae Woong: 5 articles (05/2015 - 04/2008)|
|7.||Park, Jong Kwan: 5 articles (05/2015 - 06/2010)|
|8.||Lee, Sung Won: 5 articles (05/2015 - 04/2008)|
|9.||Kwon, Jong Won: 5 articles (01/2007 - 05/2004)|
|10.||Ahn, Byoung Ok: 5 articles (01/2007 - 06/2003)|
05/01/2004 - "These results suggest that DA-8159 is an effective treatment for diabetic erectile dysfunction but further evaluation of the efficacy on human needs to be performed."
06/01/2010 - "Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial."
08/01/2015 - "Re: Efficacy of Once-Daily Administration of Udenafil for 24 Weeks on Erectile Dysfunction: Results from a Randomized Multicenter Placebo-Controlled Clinical Trial."
05/01/2015 - "Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: results from a randomized multicenter placebo-controlled clinical trial."
05/01/2011 - "To investigate the efficacy of repeated dosing with a PDE5 inhibitor on cognitive function and somatization in patients with erectile dysfunction, 27 patients with erectile dysfunction received udenafil (100 mg) at 3-day intervals for 2 months. "
01/01/2014 - "Udenafil is as effective in the treatment of diabetes mellitus-associated ED as other PDE5Is. "
07/01/2011 - "A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus."
05/01/2004 - "In this study, we investigated the in vitro effects of DA-8159 on cavernosal smooth muscle relaxation and the in vivo erectogenic potential in diabetic rabbits, since erectile dysfunction is a well-known sequela of diabetes mellitus. "
04/01/2013 - "Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia."
09/01/2004 - "Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin."
09/01/2015 - "Udenafil-attenuated myocardial fibrosis and apoptosis. "
01/01/2009 - "Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. "
11/01/2003 - "In addition, DA-8159 prevented myocardial fibrosis induced by MCT. "
08/01/2003 - "In myocardial morphology, MCT-induced myocardial fibrosis was markedly prevented by DA-8159. "
07/01/2010 - "These results demonstrate that long-term administration of udenafil ameliorates penile hypoxia and fibrosis induced by cavernous nerve resection. "
|4.||Spinal Cord Injuries (Spinal Cord Injury)
12/01/2003 - "Efficacy of DA-8159, a new PDE5 inhibitor, for inducing penile erection in rabbits with acute spinal cord injury."
12/01/2003 - "The aim of this study was to investigate the effects of DA-8159 on inducing a penile erection in rabbits with an acute spinal cord injury (ASCI). "
06/01/2003 - "These results demonstrate that DA-8159 may be a useful treatment option for erectile dysfunction in patients with or without a spinal cord injury, but further evaluation of the effects of DA-8159 on humans must be performed."
09/01/2005 - "This study examined the effects of a new phosphodiesterase type 5 inhibitor, DA-8159, on erectile function associated with hypercholesterolemia. "
09/01/2005 - "These results suggest that DA-8159 is beneficial for erectile dysfunction in a rat hypercholesterolemic model and provided a rationale for the potential use of DA-8159 for treating erectile dysfunction secondary to hypercholesterolemia."
01/23/2007 - "To provide molecular insight into pathophysiology of hypercholesterolemia-related ED and to investigate the effects of Udenafil, a phosphodiesterase type 5 (PDE5) inhibitor, on gene expression, we performed microarray gene expression analysis via gene discovery methods using GenoCheck platinum cDNA chip (Ansan, S. "
09/01/2005 - "First of all, in order to investigate whether chronic administration of DA-8159 prevents the development of erectile dysfunction associated with hypercholesterolemia, male SD rats were divided into four groups (normal control, hypercholesterolemic control, DA-8159 5 or 20 mg/kg/day). "
|1.||Type 5 Cyclic Nucleotide Phosphodiesterases
|2.||Brain-Derived Neurotrophic Factor (BDNF)
|3.||Serotonin (5 Hydroxytryptamine)
|4.||Prostatectomy (Retropubic Prostatectomy)